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Abstract
Microcalcifications are one of the most common abnormalities detected by mammography for the
diagnosis of breast cancer. However, the detection of microcalcifications and correct diagnosis of
breast cancer are limited by the sensitivity and specificity of mammography. Therefore, the
objective of this study was to investigate the potential of bisphosphonate-functionalized gold
nanoparticles (BP-Au NPs) for contrast-enhanced radiographic detection of breast
microcalcifications using two models of breast microcalcifications which allowed for precise
control over levels of hydroxyapatite (HA) mineral within a low attenuating matrix. First, an in
vitro imaging phantom was prepared with varying concentrations of HA uniformly dispersed in an
agarose hydrogel. The X-ray attenuation of HA-agarose compositions labeled by BP-Au NPs was
increased by up to 26 HU compared to unlabeled compositions for HA concentrations ranging
from 1–10 mg/mL. Second, an ex vivo tissue model was developed to more closely mimic the
heterogeneity of breast tissue by injecting varying concentrations of HA in a Matrigel carrier into
murine mammary glands. The X-ray attenuation of HA-Matrigel compositions labeled by BP-Au
NPs was increased by up to 289 HU compared to unlabeled compositions for HA concentrations
ranging from 0.5–25 mg/mL, which included an HA concentration (0.5 mg/mL) that was
otherwise undetectable by micro-computed tomography. Cumulatively, both models demonstrated
the ability of BP-Au NPs to enhance contrast for radiographic detection of microcalcifications,
including at a clinically-relevant imaging resolution. Therefore, BP-Au NPs may have potential to
improve clinical detection of breast microcalcifications by mammography.
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1. Introduction
Breast cancer is the most common cancer and second leading cause of cancer-related deaths
among women in the United States [1]. Early detection by mammography is the current
clinical gold standard in breast cancer screening and is considered to be the best hope for
controlling the disease due to a demonstrated decrease in breast cancer mortality [2,3].
Microcalcifications are one of the most common abnormalities detected by mammography
[4,5] and are coincident with 30–50% of breast cancers detected by mammograms [6–8].
Microcalcifications are deposits of hydroxyapatite (HA) or calcium oxalate (CaOx) mineral
within the breast tissue [9–12], which exhibit high X-ray attenuation relative to the low
attenuating breast tissue facilitating detection by mammography.
The detection of microcalcifications and correct diagnosis of breast cancer are limited by the
sensitivity and specificity of mammography. Mammographically-detected
microcalcifications range in size from 0.1–1.0 mm, but smaller microcalcifications are
detected histologically [6]. Limitations in sensitivity can result in the missed detection of
cancerous lesions at an early stage, or false negatives, and therefore lost opportunity for
early treatment [13]. Studies have reported that 10–30% of all breast lesions are missed
during routine mammographic screening [6,14]. Limitations in specificity can result in false
positives [15] and unnecessary biopsies, which increase patient anxiety and healthcare costs
[16]. The detection of microcalcifications is limited by their small size and the presence of
other structures in the breast, such as fibrous tissue, ducts and blood vessels, which may be
mistaken for microcalcifications due to exhibiting greater X-ray attenuation than
surrounding tissue [6]. Therefore, improvements are needed for detecting
microcalcifications during mammographic screening for breast cancer.
X-ray contrast agents [17] could be used to improve the sensitivity and specificity of
detecting breast microcalcifications by mammography. Improved sensitivity could be
achieved by providing enhanced X-ray contrast for small microcalcifications that are
otherwise below the detection limit of mammography, thus enabling earlier detection.
Improved specificity could be achieved using a targeted X-ray contrast agent.
Gold nanoparticles (Au NPs) have received recent attention as a potential X-ray contrast
agent due to exhibiting greater X-ray attenuation and improved vascular retention compared
to iodinated molecular agents [18–20]. Additionally, Au NPs are widely reported to be non-
cytotoxic, readily synthesized, and readily surface functionalized for colloidal stability and
targeted delivery [21]. Au NPs surface functionalized with ligands such as antibodies [22–
25], peptides [26] or other tumor-specific biomarkers [27] have demonstrated potential as an
actively targeted X-ray contrast agent for cancer cells in vitro or tumors in vivo.
Bisphosphonate-functionalized Au NPs (BP-Au NPs) were recently investigated as a
targeted X-ray contrast agent for microdamage in bone tissue [28,29]. Bisphosphonates,
such as alendronate, are used as a pharmaceutical in the treatment of osteoporosis [30] due
to exhibiting a high binding affinity for HA, the mineral component of bone [31]. BP-Au
NPs exhibited colloidal stability in physiological media, a high binding affinity for HA
crystals in vitro, and targeted labeling of damaged bone tissue in vitro [28,29]. Interestingly,
HA is also the mineral component of the type of breast microcalcifications known to be
associated with malignant lesions [9–12,32].
Therefore, the objective of this study was to investigate the potential of BP-Au NPs for
contrast-enhanced radiographic detection of breast microcalcifications. Two models of
breast microcalcifications were developed for precisely controlling levels of HA mineral
within a low attenuating matrix. First, an in vitro imaging phantom was prepared with
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varying concentrations of HA uniformly dispersed in an agarose hydrogel. Second, an ex
vivo murine tissue model was developed to more closely mimic the heterogeneity of breast
tissue, and also lay the groundwork for an in vivo model, by injecting varying concentrations
of HA in a Matrigel carrier into the fat pad of the number 4 mouse mammary gland.
2. Materials and Methods
2.1. Synthesis and characterization of BP-Au NPs
Au NPs were synthesized to a mean particle diameter of ~13 nm using the citrate reduction
method [33], as previously described in detail [28,29]. Briefly, 0.1 g gold (III) chloride
trihydrate (HAuCl4·3H2O, ≥99.9%, Sigma-Aldrich, St. Louis, MO) was added to 500 mL
de-ionized (DI) water and brought to a boil while stirring. Once boiling, 0.5 g of trisodium
citrate dihydrate (Na3C6H5O7·2H2O, ACS reagent, >99%, Sigma-Aldrich) was added to the
gold solution and left to boil, while covered, for 20 min before removing heat and stirring
overnight. The solution volume was adjusted back to 500 mL after reaching room
temperature, resulting in a final solution with a gold concentration of ~0.5 mM and a red
wine color.
Au NPs were prepared for bisphosphonate surface functionalization by mixing 240 mL of
as-synthesized Au NPs with 10 mL 2 wt% polyvinyl alcohol (PVA 10–98, 61,000 Da,
Fluka, St. Louis, MO) and 5.8 g ion exchange resin (Dowex Marathon, MR-3, Sigma-
Aldrich, St. Louis, MO) to remove excess ions. The spent resin was then filtered from the
Au NPs (grade 3, Whatman, Piscataway, NJ). Au NPs were surface functionalized with
alendronate sodium trihydrate (C4H12NaNO7P2·3H2O, ≥97%, Sigma-Aldrich, St. Louis,
MO), which provided a primary amine for binding gold opposite a bisphosphonate
functional group for targeting calcium in HA. Four mL of a 0.01 M solution of alendronate
was added to 250 mL of PVA-Au NPs and left to stir overnight. Excess bisphosphonate
molecules were removed by dialysis (Spectra/Por, MWCO = 3500 Da, Spectrum
Laboratories, Rancho Dominquez, CA) against DI water for 3 d, changing the water at least
3 times daily.
BP-Au NPs have been thoroughly characterized in previous studies, which included
measurements of the mean particle diameter, mean hydrodynamic diameter, colloidal
stability in physiological media, and bisphosphonate surface density [28,29]. All BP-Au NPs
prepared in this study were characterized by dynamic light scattering (DLS, Zetasizer Nano
ZS90, Malvern Instruments Ltd., Worcestershire, UK) and ultraviolet-visible (UV-vis)
spectroscopy (Nanodrop 200C, Thermo Scientific, Wilmington, DE) to ensure consistency
in the mean hydrodynamic diameter and colloidal stability, respectively. The hydrodynamic
diameter was measured using DLS after diluting as-prepared BP-Au NPs in DI water to a
final gold concentration of ~0.5 μM and reported as the mean of three samples. Colloidal
stability was verified by measuring the surface plasmon resonance (SPR) peak using UV-vis
spectroscopy after diluting as-prepared BP-Au NPs in DI water to a final gold concentration
of 0.4 mM. Gold concentrations were measured using inductively coupled plasma-optical
emission spectroscopy (ICP-OES, Optima 3000, Perkin Elmer, Inc. Waltham, MA) after
acidifying with 3% aqua regia (3 HCl:1 HNO3). Calibration curves were created by diluting
certified standard gold solutions (Assurance Grade, SPEX CertiPrep, Metuchen, NJ).
2.2. In vitro imaging phantom
An in vitro imaging phantom of breast microcalcifications was created by mixing varying
concentrations of HA crystals in an agarose hydrogel. Whisker-shaped HA crystals,
exhibiting a mean length and width of ~18 x ~2 μm, were synthesized using the chelate
decomposition method, as described elsewhere [34]. The specific surface area of the HA
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crystals was 5.63 m2/g as measured using Brunauer-Emmett-Teller (BET) N2 adsorption
(Autosorb-1, Quantachrome Instruments, Boynton Beach, FL) [28]. HA crystals were added
to a 2 wt% agarose hydrogel (Sigma-Aldrich, St. Louis, MO) at varying HA concentrations
of 0, 0.5, 1.0, 2.5, 5.0, 10, and 25 mg/mL and gelled into 10 μL pellets at 4°C. The HA
concentration in each pellet was verified by measuring the calcium concentration with ICP-
OES using the methods described above. Calibration curves were created by diluting
certified standard calcium solutions (Assurance Grade, SPEX CertiPrep).
HA-agarose pellets labeled by BP-Au NPs were prepared by labeling HA crystals with BP-
Au NPs prior to forming the pellets. HA concentrations of 0.5, 1.0, 2.5, 5.0, 10, and 25 mg/
mL were incubated in DI water containing 40 mg/L (0.2 mM) BP-Au NPs for 24 h to allow
for maximum binding of the BP-Au NPs to the HA crystals [28]. Thus, each HA
concentration was exposed to the same BP-Au NP concentration for the same length of time.
Unbound BP-Au NPs were separated from HA crystals by centrifugation at ~700g for 2 min.
HA crystals labeled by BP-Au NPs were collected using 0.45 μm filter paper (Nylaflo, Pall
Corporation, Ann Arbor, MI), rinsed with 10 mL DI water, dried overnight in an oven at
37°C, and stored under vacuum. Labeled HA crystals were mixed with 2 wt% agarose
solution and gelled into 10 μL pellets at 4°C.
Labeled and unlabeled HA-agarose pellets were imaged in Eppendorf tubes by micro-
computed tomography (micro-CT, μCT-80, Scanco Medical AG, Brüttisellen, Switzerland)
at 45 kVp, 177 μA, 600 ms integration time, and 10 μm resolution for 250 slices. The
standard 0.5 mm aluminum filter was removed to increase the number of low energy
photons to approximate mammographic imaging. The mean (±standard deviation) sampled
volume for each pellet was 5.2 (1.3) mm3. The measured mean linear attenuation coefficient
of the HA-agarose pellets was converted to Hounsfield units (HU) using an internal sample
calibration for air (−1000 HU) and water (0 HU) controls measured from 10 slices in the
same sample tube. The X-ray attenuation measured for each labeled and unlabeled HA
concentration was reported in HU as the mean (±standard deviation) of five samples.
The percent of BP-Au NPs bound to HA crystals was measured as the concentration of
unbound BP-Au NPs subtracted from the initial BP-Au NP concentration, divided by the
initial BP-Au NP concentration. The initial gold concentration and the concentration of
unbound BP-Au NPs were measured using ICP-OES, as described above. The mass of BP-
Au NPs bound per HA surface area (mg Au/m2 HA), or surface density, was calculated
using the measured specific surface area of the HA crystals. The mean (±standard deviation)
percent of BP-Au NPs bound and mass of BP-Au NPs bound per HA surface area were
measured from three samples for each HA concentration. The presence and surface density
of BP-Au NPs on HA crystal surfaces were also verified using field emission scanning
electron microscopy (FE-SEM, 400 XHR, FEI, Hillsboro, OR). Specimens were prepared by
dropping a solution of HA crystals labeled with BP-Au NPs in 90% ethanol on a heated
SEM stub and coating with 2.5 nm iridium by sputter deposition. Specimens were imaged at
an accelerating voltage of 5 kV and current of 6.3 pA.
2.3. Ex vivo tissue model
Mature mammary glands (MGs) from 8–12 week old nulliparous FVB female mice (Charles
River Laboratories International, Inc., Wilmington, MA) were used to develop an ex vivo
tissue model of microcalcifications. All studies were approved by the Institutional Animal
Care and Use Committee at the University of Notre Dame and were conducted in
accordance with the guidelines of the U.S. Public Health Service Policy for Humane Care
and Use of Laboratory Animals. All efforts were made to minimize suffering of the mice.
Mice were euthanized and dissected to expose the left and right number 4 MGs. HA crystals
were mixed with Matrigel (BD Matrigel, BD Sciences, Bedford, MA), a hydrogel comprised
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of extracellular matrix proteins, at HA concentrations of 0, 0.5, 5.0, and 25 mg/mL, and HA-
Matrigel compositions were immediately injected into the fat pad of MGs at a dose of 50
μL.
HA-Matrigel compositions labeled with BP-Au NPs were prepared by labeling HA crystals
with BP-Au NPs prior to mixing with Matrigel. Three concentrations of HA crystals, 0.5, 5
and 25 mg/mL, were labeled with two different concentrations of BP-Au NPs (10 mg/L and
74 mg/L) for 24 h using the same methods described above for the in vitro imaging
phantom. After labeling, unbound BP-Au NPs were separated from HA crystals by
centrifugation at ~700g for 2 min. HA crystals labeled by BP-Au NP were collected using
0.45 μm filter paper (Nylaflo), rinsed with 10 mL DI water, dried overnight in an oven at
37°C, and stored under vacuum. Labeled HA crystals were mixed with Matrigel and injected
into the MGs, as described above.
MGs containing HA-Matrigel compositions were imaged ex vivo by micro-CT within 24 h
after injection. Labeled and unlabeled HA-Matrigel compositions were allowed to set for 1
min, before MGs were dissected and stored in phosphate buffered saline at 4°C. In order to
eliminate movement of the MGs and maintain tissue hydration during micro-CT imaging,
MGs were embedded in 2% agarose and placed in a polyethylene specimen tube (14 mm
diameter). MGs were imaged by micro-CT (μCT-80, Scanco Medical AG) at 45 kVp, 177
μA, and 600 ms integration time at a high resolution (10 μm) and a more clinically-relevant
lower resolution (100 μm). The standard 0.5 mm aluminum filter was removed to increase
the number of low energy photons to approximate mammographic imaging. The volume of
interest (VOI) for analysis was 3.01 mm3 at 10 μm resolution or 5.67 mm3 at 100 μm
resolution for each MG, which included both the HA-Matrigel composition and MG tissue.
The measured mean linear attenuation coefficient of the VOI was converted to Hounsfield
units (HU) using an internal calibration for air (−1000 HU) and water (0 HU) controls that
were included in the first and last micro-CT scan performed each day. The X-ray attenuation
measured for each labeled and unlabeled HA concentration was reported in HU as the mean
(±standard deviation) of five samples.
The percent of BP-Au NPs bound to HA crystals and the mass of BP-Au NPs bound per HA
surface area (mg Au/m2 HA) were determined from the initial gold concentration and
concentration of the unbound BP-Au NPs measured by ICP-OES, as described above. The
mean (±standard deviation) percent of BP-Au NPs bound and mean mass of BP-Au NPs
bound per HA surface area were measured from three samples for each HA concentration.
2.4. Statistical Methods
The accuracy and precision of the in vitro imaging phantom model was validated by
comparing the expected HA concentration within 10 μL HA-agarose pellets with the
measured HA concentration from ICP-OES using a paired t-test and linear least squares
regression, respectively (JMP 10.0. SAS Institute, Inc., Cary, NC). For both the in vitro and
ex vivo models, X-ray attenuation was correlated with HA concentration using linear least
squares regression and differences in the X-ray attenuation of labeled and unlabeled HA
concentrations were examined using two-way analysis of variance (ANOVA). Differences
in the binding of BP-Au NPs to HA crystals in either model were also examined using one-
and two-way ANOVA. Post hoc comparisons were performed using unpaired Student’s t-
tests. The level of significance for all tests was set at p < 0.05.
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3. Results and Discussion
3.1. Characterization of BP-Au NPs
BP-Au NPs were synthesized using the citrate reduction method and surface functionalized
with alendronate, a bisphosphonate with a primary amine for binding to gold surfaces
opposite phosphonate groups for targeting calcium ions on HA crystal surfaces (Fig. 1a).
Resulting BP-Au NPs were spherical and monodispersed with a mean (±standard deviation)
particle diameter of 12.8 (1.6) nm (Fig. 1b), as measured by TEM [28]. The colloidal
stability of BP-Au NPs was characterized using DLS and UV-vis spectroscopy. The mean
(±standard deviation) hydrodynamic diameter was 45.8 (1.5) nm, as measured by DLS (Fig.
1c), which was consistent with previously published results for 13 nm BP-Au NPs [29]. The
characteristic SPR peak was observed at ~527 nm in UV-vis spectroscopy (Fig. 1d), which
was also consistent with previously published results for 13 nm BP-Au NPs [28,29]. The
hydrodynamic diameter and characteristic SPR peak were characterized for each batch of
BP-Au NPs synthesized and over time to ensure that BP-Au NPs remained well-dispersed
and stable.
Colloidal stability is critically important for a targeted nanoparticle contrast agent as
nanoparticles must remain dispersed in relevant media for targeted delivery. As-prepared Au
NPs are stable in water, but are typically unstable in physiological media, requiring the
addition of appropriate functional ligands [29,35]. BP-Au NPs were previously shown to
exhibit colloidal stability in phosphate buffered saline (PBS) and fetal bovine serum (FBS)
for at least 7 d due to a combination of the steric and electrostatic stabilizing effects of
bisphosphonate ligands [29].
3.2. In vitro imaging phantom
An in vitro imaging phantom was developed to investigate the potential of BP-Au NPs for
contrast-enhanced X-ray detection of microcalcifications. Microcalcifications in breast
tissue were modeled by mixing varying concentrations of HA crystals in an agarose
solution. Agarose provided a matrix with low X-ray attenuation for uniformly dispersing the
HA crystals. The range of HA concentrations was used to model different stages of
microcalcification burden, including the earliest stages when microcalcifications may be too
small to be detected by mammography [6].
The accuracy and precision of the model was validated by correlating the expected HA
concentration within HA-agarose pellets against the measured HA concentration from ICP-
OES (Fig. 2). Measured HA concentrations were less than expected HA concentrations (p <
0.05, paired t-test), most likely due to losses of HA during mixing and subsequent analysis,
but the mean error was only −8.3%, indicating reasonable accuracy. More importantly,
linear least squares regression indicated that HA concentrations were highly reproducible
(R2 = 0.992). Therefore, the in vitro imaging phantom was determined to exhibit sufficient
accuracy and precision for investigating the effects of the HA concentration and BP-Au NP
labeling on X-ray attenuation.
The X-ray attenuation of unlabeled and BP-Au NP labeled HA concentrations was measured
using micro-CT. X-ray attenuation increased with increasing HA concentration for both
unlabeled and labeled HA groups (p < 0.001, ANOVA) (Fig. 3). The X-ray attenuation of
unlabeled HA exhibited a linear relationship with HA concentration (R2 = 0.997), as
expected. All unlabeled HA concentrations exhibited significantly greater X-ray attenuation
compared to the agarose-only (0 mg/mL HA) control (p < 0.005, t-test). Labeling by BP-Au
NPs enhanced the X-ray attenuation of HA concentrations ranging from 1–10 mg/mL
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compared to unlabeled HA at the same concentration (p < 0.005, t-test) (Fig. 3). A
maximum differential contrast enhancement of 26 HU was achieved at 5 mg/mL HA.
The X-ray attenuation of the lowest (0.5 mg/mL) and highest (25 mg/mL) HA
concentrations were not increased when labeled by BP-Au NPs. Therefore, the percent of
the BP-Au NP dose bound to HA and the mass of BP-Au NPs bound per HA surface area
(mg Au/m2 HA) were measured to investigate differences with HA concentration. Complete
binding of the BP-Au NP dose occurred at HA concentrations ≥ 2.5 mg/mL and the percent
binding decreased with decreasing HA concentration (p < 0.0001, ANOVA) (Fig. 4a). On
the other hand, HA crystals surfaces were saturated with BP-Au NPs at HA concentrations ≤
2.5 mg/mL and the surface density decreased with increasing HA concentration (p < 0.0001,
ANOVA) (Fig. 4b). The decreased surface density of BP-Au NPs with increasing HA
concentration was also directly confirmed by electron microscopy (Fig. 5). Thus, BP-Au
NPs were unable to provide enhanced X-ray contrast at 0.5 mg/mL and 25 mg/mL due to a
limited number of total available binding sites at low HA concentrations and a limited
number of BP-Au NPs available for binding at high HA concentrations, respectively.
These results suggest a limit to contrast enhancement at HA concentrations ≤ 0.5 mg/mL
using this model, since HA crystal surfaces were saturated with BP-Au NPs (Fig. 4b).
Contrast enhancement at the lowest HA concentration (0.5 mg/mL) would seem to be
advantageous for detecting HA concentrations otherwise virtually undetectable over the
background signal. Therefore, contrast enhancement at HA concentrations ≤ 0.5 mg/mL
would require either more sensitive imaging methods or the delivery of a greater mass
concentration of Au NPs. On the other hand, a lower limit in HA concentration for contrast
enhancement might also be advantageous to prevent false positives. Thus, the level of such a
limit or the minimum microcalcification burden for clinical breast cancer diagnosis is
critically important but currently unknown.
These results also suggest that contrast enhancement could be achieved at higher HA
concentrations (e.g., 25 mg/mL) by simply increasing the BP-Au NP dose. However,
contrast enhancement is not necessary at high HA concentrations (e.g., 25 mg/mL) that are
readily detected without contrast enhancement. Moreover, an upper limit in HA
concentration for contrast enhancement may be advantageous for determining
microcalcification burden. Therefore, an optimal BP-Au NP dose must be determined for
providing sufficient contrast enhancement over the most appropriate range of HA
concentrations, preferably below the detection limits in the absence of contrast
enhancement. For this reason, a higher and lower BP-Au NP concentration was investigated
in the ex vivo tissue model described below.
Interestingly, the greatest X-ray contrast enhancement in this model occurred at an HA
concentration of 5 mg/mL. Unlabeled HA at 5 mg/mL exhibited ~21 HU, which is similar to
the X-ray attenuation of the glandular tissue component of human breast tissue at 45 kVp
[36], and labeling with BP-Au NPs increased the X-ray attenuation to ~47 HU. This
suggests that BP-Au NPs may be particularly useful for providing enhanced contrast to
detect microcalcifications in dense breast tissue, which is composed of relatively greater
amounts of glandular tissue. This finding is clinically significant because sensitivity for the
detection microcalcifications is dramatically reduced in women with radiographically dense
breast tissue [37–39], while increased breast density is associated with an increased risk of
cancer [40].
The in vitro imaging phantom demonstrated the ability of BP-Au NPs to enhance X-ray
contrast for the detection of microcalcifications (Fig. 3), but was not without limitations.
The measured X-ray attenuation of agarose was approximately −14 HU or 1.189 cm−1 at 45
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kVp, which provided a good average approximation, but was higher than adipose tissue
(−260 HU at 45 kVp) and lower than glandular tissue (20 HU at 45 kVp) [36]. Additionally,
HA crystals were uniformly dispersed within the agarose matrix. However, breast
microcalcifications may appear as single crystals or clustered aggregates of many crystals
and the degree of clustering may be used to distinguish between malignant and benign
lesions [41,42]. Therefore, an ex vivo tissue model was developed to more closely
recapitulate the heterogeneity of microcalcifications in breast tissue.
3.3. Ex vivo murine tissue model
An ex vivo murine tissue model was developed to more closely mimic the heterogeneity of
breast tissue and also lay the groundwork for an in vivo model. Murine MGs are important
models for studying human breast cancer [43] and were used in this study to mimic the low
X-ray attenuation of adipose tissue in the human breast [36]. Varying concentrations of
unlabeled and labeled HA were mixed with Matrigel and injected into the fat pad of excised
murine MGs to model the heterogeneity of microcalcifications in breast tissue. Varying HA
concentrations were used to model different levels of microcalcification burden, including
the earliest stages when microcalcifications may be too small to be detected by
mammography [6]. The injection volume and HA concentration were readily tailored
providing a straightforward and reproducible model for creating microcalcifications of
known HA concentration for investigating X-ray contrast agents. Breast microcalcifications
have also been biologically-induced in mice and rats via implanted cancer cells [44] and
delivery of exogenous growth factors [45–47], respectively, but these models require
separate measurements to quantify the HA concentration or microcalcification burden rather
than offering a priori control.
X-ray attenuation increased with increasing HA concentration for both unlabeled and
labeled HA-Matrigel compositions imaged by micro-CT at both high (10 μm) and low (100
μm) resolution (p < 0.001, ANOVA) (Fig. 6). The X-ray attenuation of unlabeled HA
exhibited a linear relationship with HA concentration at both high and low imaging
resolution (R2 > 0.993), as expected. Unlabeled HA concentrations of 5 and 25 mg/mL
exhibited significantly greater X-ray attenuation compared to the Matrigel control (0 mg/mL
HA) at both high (p < 0.005, t-test) and low (p < 0.05, t-test) resolution, but differences
between 0.5 mg/mL HA and the Matrigel control were not statistically significant (p > 0.28)
(Fig. 6). Therefore, HA-Matrigel compositions containing 0.5 mg/mL HA were undetectable
relative to the Matrigel-only control. Interestingly, the microcalcifications created at 0.5 mg/
mL HA appeared to be less than 0.1 mm in size in micro-CT images, and increased in size
with HA concentration to greater than 1.0 mm at 25 mg/mL HA (Fig. 7). Therefore, the
microcalcifications produced by the model included sizes below the detection limit of
mammography (< 0.1 mm) and within the detection limits of mammography (0.1–1.0 mm)
[6].
Differences in the X-ray attenuation between unlabeled and BP-Au NP labeled HA
concentrations within murine MGs were also measured by micro-CT at both high (10 μm)
and low (100 μm) resolution. Using high resolution imaging (10 μm), labeling by either
dose of BP-Au NPs enhanced the X-ray attenuation of all HA concentrations compared to
unlabeled HA at the same HA concentration (p < 0.05, t-test), including at an HA
concentration (0.5 mg/mL) that was otherwise undetectable by micro-CT (Fig. 6a). Using
low resolution imaging (100 μm), labeling by either dose of BP-Au NPs enhanced the X-ray
attenuation compared to unlabeled HA at an HA concentration of 5 mg/mL (p < 0.05, t-test)
(Fig. 6b). Note, however, that non-significant differences between unlabeled and labeled
HA-Matrigel compositions at 0.5 and 25 mg/mL HA were nearly significant (p < 0.13), but
underpowered. Post hoc power analysis indicated that these differences would become
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statistically significant if the sample size were increased from 5 to 9 specimens. The
differential contrast measured for BP-Au NP labeled HA concentrations was visually
apparent in grayscale micro-CT images (Fig. 7). A maximum differential contrast
enhancement of 289 or 242 HU was achieved at 25 mg/mL HA with the higher gold dose
when imaging at high or low resolution, respectively (Fig. 6).
Results from the ex vivo murine tissue model showed that BP-Au NPs provided enhanced
contrast at all HA concentrations (Fig. 6a), including the lowest (0.5 mg/mL) and highest
(25 mg/mL) HA concentrations which were not able to be detected in the in vitro phantom
(Fig. 3). Moreover, the magnitude of differential contrast obtained with the ex vivo tissue
model was significantly greater than that obtained with the in vitro phantom. The greater
sensitivity and contrast enhancement in the tissue model was most likely due to the lower
mean background signal in the tissue model (~−300) compared to the imaging phantom (~
−14 HU).
Imaging resolution was important to investigate for clinical translation as current
mammographic imaging systems have a microcalcification detection limit of ~100 μm [48].
Therefore, tissue samples were imaged at both high resolution (10 μm) and a more
clinically-relevant lower resolution (100 μm). High-resolution imaging provided excellent
visualization of the structure of the MGs, including the ducts which attenuated more than the
adipose tissue (Fig. 7a), and detected enhanced contrast for BP-Au NP labeled HA-Matrigel
compositions at each HA concentration (Fig. 6a). However, this level of resolution is not yet
available clinically. At the more clinically-relevant lower resolution (100 μm), the ducts
were not readily visualized (Fig. 7b), but enhanced contrast was still able to be detected for
BP-Au NP labeled HA-Matrigel compositions (Fig. 6b), though some differences were
underpowered at the lowest and highest HA concentration, as discussed above. This is a
very promising result, as future studies will continue to investigate BP-Au NPs in in vivo
models using pre-clinical imaging systems with resolution lower than 10 μm.
All differences in X-ray attenuation between the low (10 mg/L) and high (74 mg/L) BP-Au
NP dose at the same HA concentration were not statistically significant (p > 0.23, t-test).
However, the low and high dose were chosen to be below and above, respectively, the
equilibrium saturation of Au NPs bound to HA surfaces [28], which was expected to lead to
differences in the surface density of BP-Au NPs labeling HA crystals and the measured X-
ray attenuation. Therefore, the percent of the BP-Au NP dose bound to HA and the mass of
BP-Au NPs bound per HA surface area (mg Au/m2 HA) were measured to investigate
differences with HA concentration and the BP-Au NP dose. Complete binding occurred at
HA concentrations ≥ 5.0 mg/mL for either BP-Au NP dose, but the percent binding was
significantly lower (p < 0.001, t-test) for the higher BP-Au NP dose at a lower HA
concentration (0.5 mg/mL) where binding was incomplete (Fig. 8a). On the other hand, the
surface density of BP-Au NPs was significantly greater for the higher BP-Au NP dose at
each HA concentration (p < 0.0001, t-test) and decreased with increasing HA concentration
for either BP-Au NP dose (p < 0.0001, ANOVA) (Fig. 8b). These differences in the surface
density of BP-Au NPs were also directly confirmed by electron microscopy (not shown).
Thus, a greater concentration of BP-Au NPs was able to drive equilibrium surface
adsorption toward a greater surface density of BP-Au NPs labeling HA crystals surfaces, as
expected [28]. However, the greater mass concentration of gold labeling HA crystals using
the higher dose of BP-Au NPs (Fig. 8b) did not translate into a statistically significant
increase in X-ray attenuation (Fig. 6). This suggests that while the higher BP-Au NP dose
provided additional Au NPs labeling HA crystal surfaces, the additional dose was
unnecessary for contrast-enhanced X-ray detection as the low BP-Au NP dose was alone
sufficient to provide enhanced contrast at all HA concentrations (Fig. 6). In other words, the
additional BP-Au NP dose provided negligible additional increase in contrast compared to
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the contrast between labeled and unlabeled HA concentrations. Note, however, that this
result does not preclude the benefits of a higher BP-Au NP dose for in vivo delivery where
only a small portion of any dose will reach the targeted tissue [26,27].
3.4. Clinical and Scientific Implications
Breast microcalcifications are markers for breast cancer and are one of the most common
abnormalities detected by mammography during routine screening [4–7]. However, due to
limitations in the sensitivity and specificity of mammography, some microcalcifications and
associated breast lesions go undetected [49]. Therefore, in this study, we demonstrated that a
targeted X-ray contrast agent provided enhanced contrast for the detection of
microcalcifications that were otherwise undetectable with micro-CT imaging. In addition,
we developed two models of breast microcalcifications, an in vitro imaging phantom and ex
vivo murine tissue model, to investigate the potential of BP-Au NPs as a targeted X-ray
contrast agent.
To our knowledge, this is the first study demonstrating the use of surface functionalized Au
NPs as a targeted contrast agent for breast microcalcifications. Labeling by BP-Au NPs
enabled contrast-enhanced X-ray detection of HA compositions in in vitro and ex vivo
models of breast microcalcifications. Contrast-enhanced detection of microcalcifications
opens the possibility of improving the early detection of microcalcifications during breast
cancer screening. A number of other methods are also under investigation to improve
sensitivity for the detection of microcalcifications, including computer-aided detection
algorithms [6,50,51], dual-energy mammography [52], computed tomography [53–55],
high-resolution ultrasound [56], near-infrared fluorescence imaging with targeted molecular
agents [57,58], and Raman spectroscopy [12,59,60]. However, a targeted X-ray contrast
agent, such as BP-Au NPs, could provide a more sensitive and more readily translatable
diagnostic tool that could be used in conjunction with current mammography systems.
This study also demonstrated the utility of two models of breast microcalcifications,
including an in vitro imaging phantom and ex vivo murine tissue model, for evaluating
targeted contrast agents. In vivo models of breast microcalcifications have been developed in
mice using implanted tumor cells [44] and in rats using exogenous growth factors [45–47].
These models are more biologically-relevant and will be useful for future investigations for
the targeted delivery of BP-Au NPs and radiographic imaging in vivo. However, the in vitro
imaging phantom and ex vivo murine tissue model afforded more precise and a priori
control over the HA concentration for an initial preclinical evaluation of a targeted contrast
agent. Moreover, the methods developed to create microcalcifications in the ex vivo tissue
model could be applied to an in vivo murine model.
The main limitation of this study was that HA crystals were labeled with BP-Au NPs in DI
water prior to being mixed with the agarose solution or Matrigel carrier. Therefore, the mass
concentration of BP-Au NPs labeling HA crystal surfaces in these models may represent a
best case scenario compared to delivery in vivo. As discussed above, only a fraction of the
initial BP-Au NP dose will reach the targeted site upon in vivo delivery [26,27]. Moreover,
the binding of BP-Au NPs to HA crystals was previously shown to be decreased in the
presence of serum proteins [28]. Therefore, the contrast enhancement achieved in this study
is encouraging since the Au NP concentration was relatively low at 10–74 mg/L. Previous
studies on X-ray imaging have utilized Au NP concentrations ranging 0.6–2500 mg/L in
vitro [22,27] and 3000–270,000 mg/L in vivo [18–20,23–27].
Another important limitation was the small size and low background intensity of the
specimens in this study relative to human breast mammography. The level of contrast
enhancement, or signal-to-noise ratio, is expected to decrease with increased specimen
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thickness or density, due to increased absorption and scattering of photons by the
background material or tissue. Nonetheless, this study was an important first step to
demonstrate feasibility prior to ongoing studies investigating the targeted delivery of BP-Au
NPs and radiographic imaging in mice in vivo, including models of radiographically dense
breast tissue.
4. Conclusions
Contrast-enhanced detection of breast microcalcifications using BP-Au NPs was
investigated using an in vitro imaging phantom and ex vivo murine tissue model comprising
varying and reproducible levels of HA crystals. X-ray attenuation increased linearly with
increasing HA concentration, as expected. The X-ray attenuation of HA compositions
labeled by BP-Au NPs was significantly increased compared to unlabeled compositions at
the same HA concentration, including an HA concentration that was otherwise undetectable
by micro-CT. Contrast-enhancement was shown to be dependent on achieving a sufficient
mass concentration of BP-Au NPs labeling HA crystals surfaces. Thus, BP-Au NPs enabled
contrast-enhanced detection of breast microcalcifications by X-ray imaging, including at a
clinically-relevant imaging resolution. BP-Au NPs may therefore have potential to improve
clinical detection of breast microcalcifications by mammography.
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Fig. 1.
(a) Gold nanoparticles were surface functionalized with alendronate, a bisphosphonate with
a primary amine for binding to gold surfaces opposite phosphonate groups for targeting
calcium ions on HA crystal surfaces. (b) Representative TEM micrograph showing spherical
and monodispersed BP-Au NPs. (c) The particle diameter distribution measured by TEM
and the hydrodynamic diameter distribution measured by DLS. The mean (±standard
deviation) physical particle diameter and hydrodynamic diameter were 12.8 (1.6) nm and
45.8 (1.5) nm, respectively. (d) UV-vis spectra of BP-Au NPs showing the surface plasmon
resonance peak at ~527 nm.
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Fig. 2.
The expected HA concentration (mg/mL) within 10 μL HA-agarose pellets of the in vitro
imaging phantom was validated against the measured HA concentration (mg/mL) from ICP-
OES. Error bars show one standard deviation of the mean (n = 3/group) and error bars not
shown lie within the data point. The dashed gray line shows a one-to-one equivalence.
Differences between expected and measured HA concentrations were significantly different
(p < 0.05, paired t-test), but the mean error was −8.3%, indicating reasonable accuracy.
More importantly, linear least squares regression indicated that HA concentrations were
highly reproducible (R2 = 0.992).
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Fig. 3.
The X-ray attenuation (HU) measured by micro-CT for the in vitro imaging phantom
comprising unlabeled and BP-Au NP labeled HA crystals at varying HA concentrations
within an agarose hydrogel. Error bars show one standard deviation of the mean (n = 5/
group). X-ray attenuation increased with increasing HA concentration for both labeled and
unlabeled HA-agarose pellets (p < 0.001, ANOVA). All unlabeled HA concentrations
exhibited significantly greater X-ray attenuation compared to the 0 mg/mL agarose control
(*p < 0.005, t-test). BP-Au NPs enhanced the X-ray attenuation of HA concentrations
ranging from 1–10 mg/mL compared to unlabeled HA at the same concentration (**p <
0.005, t-test).
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Fig. 4.
BP-Au NP binding to varying concentrations of HA crystals in HA-agarose pellets was
characterized by measuring the concentration of unbound BP-Au NPs using ICP-OES. (a)
The percent of BP-Au NPs bound to HA crystals showed complete binding of the BP-Au NP
dose at HA concentrations ≥ 2.5 mg/mL and decreased percent binding with decreasing HA
concentration (p < 0.0001, ANOVA). (b) The mass of BP-Au NPs bound per HA surface
area (mg Au/m2 HA) showed that HA crystals surfaces were saturated with BP-Au NPs at
HA concentrations ≤ 2.5 mg/mL and the surface density decreased with increasing HA
concentration (p < 0.0001, ANOVA). Error bars show one standard deviation of the mean (n
= 3) and error bars not shown were negligibly small.
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Fig. 5.
Representative FE-SEM micrographs showing the surface density of BP-Au NPs (arrows)
on HA crystal surfaces. The surface density appeared to increase with decreasing HA
concentration and became saturated at HA concentrations ≤ 2.5 mg/mL, in agreement with
quantitative measurements of the mass of BP-Au NPs bound per HA surface area (Fig. 4b).
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Fig. 6.
The X-ray attenuation (HU) measured by micro-CT for the ex vivo tissue model comprising
unlabeled and BP-Au NP labeled HA crystals at varying HA concentrations within HA-
Matrigel compositions injected into murine MGs and imaged at (a) high (10 μm) and (b) low
(100 μm) resolution. Error bars show one standard deviation of the mean (n = 5). X-ray
attenuation increased with increasing HA concentration for both labeled and unlabeled HA-
Matrigel compositions imaged at both high and low resolution (p < 0.0001, ANOVA). (a)
Using high resolution imaging (10 μm), BP-Au NPs enhanced the X-ray attenuation of HA-
Matrigel compositions at all HA concentrations (**p < 0.05 labeled vs. unlabeled, t-test),
including at levels that were otherwise undetectable by micro-CT (*p < 0.005 vs. control 0
mg/mL, t-test). (b) Using low imaging resolution, BP-Au NPs enhanced the X-ray
attenuation of HA-Matrigel compositions at HA concentrations ≥ 5.0 mg/mL compared to
unlabeled HA at the same concentration (**p < 0.05 labeled vs. unlabeled, t-test). All
differences in X-ray attenuation between the low (10 mg/L) and high (74 mg/L) BP-Au NP
dose at the same HA concentration were not statistically significant (p > 0.23, t-test).
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Fig. 7.
Representative grayscale micro-CT images taken at high (10 μm) and (b) low (100 μm)
resolution, showing unlabeled and BP-Au NP labeled (arrows) HA-Matrigel compositions
within excised murine MGs. Enhanced contrast was visually apparent for BP-Au NP labeled
HA compared to unlabeled HA at HA concentrations of 0.5 mg/mL and 5 mg/mL at high
resolution and 5 mg/mL HA at low resolution. The lymph node (LN) was used as an
anatomical landmark for injections.
Cole et al. Page 21
Biomaterials. Author manuscript; available in PMC 2015 February 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 8.
BP-Au NP binding to varying concentrations of HA crystals in HA-Matrigel compositions
was characterized by measuring the concentration of unbound BP-Au NPs using ICP-OES.
(a) Complete binding occurred at HA concentrations ≥ 5.0 mg/mL for either BP-Au NP
dose, but the percent binding was significantly lower (*p < 0.001, t-test) for the higher BP-
Au NP dose when binding was incomplete at a lower HA concentration (0.5 mg/mL). (b)
The mass of BP-Au NPs bound per HA surface area (mg Au/m2 HA) showed that the
surface density of BP-Au NPs was significantly greater for the higher BP-Au NP at each HA
concentration (*p < 0.0001, t-test) and decreased with increasing HA concentration for
either BP-Au NP dose (p < 0.0001, ANOVA). Error bars show one standard deviation of the
mean (n = 3) and error bars not shown were negligibly small.
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